Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.010
-0.110 (-5.19%)
Nov 20, 2024, 4:00 PM EST - Market open
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $1.79M in the quarter ending September 30, 2024, a decrease of -62.33%. This brings the company's revenue in the last twelve months to $9.92M, down -30.90% year-over-year. In the year 2023, Taysha Gene Therapies had annual revenue of $15.45M with 517.55% growth.
Revenue (ttm)
$9.92M
Revenue Growth
-30.90%
P/S Ratio
47.78
Revenue / Employee
$190,673
Employees
52
Market Cap
417.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
Dec 31, 2022 | 2.50M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DocGo | 694.97M |
Rigel Pharmaceuticals | 157.37M |
National Research | 144.16M |
Quanterix | 129.33M |
Aquestive Therapeutics | 58.90M |
Tango Therapeutics | 43.38M |
Foghorn Therapeutics | 25.52M |
Allogene Therapeutics | 43.00K |
TSHA News
- 7 days ago - Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 7 days ago - Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 19 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress - GlobeNewsWire
- 5 weeks ago - Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data - Seeking Alpha
- 3 months ago - Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire